




## ***DBPR22998: A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP $\alpha$ Axis for Cancer Immunotherapy***



**Dr. Wan-Ching Yen**  
Cancer Biology



**Dr. Chih-Hao Chen**  
Medicinal Chemistry



**Dr. Ya-Ping Chen**  
Formulation

**Ms. Pay-Ya Yang**  
Project Manager/  
Chief Administrator

**Ms. Ru-Yi Chao**  
Project Manager



**Dr. Hwei-Jiung Wang**  
Structure Biology



**Dr. Teng-Kuang Yeh** **Dr. Chuang-Tong Chen**  
Pharmacokinetics Pharmacology



**Dr. Kai-Fa Hwang**  
Protein Chemistry




# Disease Background

## CD47 and SIRP $\alpha$ Signaling – Mask Macrophage to See Cancer Cells

Cancer Cells


Macrophage



## Blockade of CD47 and SIRP $\alpha$ Signaling – Enhance Macrophage-Mediated Phagocytosis and Tumor Elimination

Cancer Cells

Macrophage



# Global CD47 Inhibitors Market Analysis

## Global CD47 Inhibitor Drug Market: Market Size and Forecast from 2023 to 2031



**Largest Region:**  
North America (40%)

**CAGR  
(2023-2031)**  
**62%**



**Market Size  
(2031)**  
**2B USD**



Source: InsightAce Analytic, Report ID: 1290, 5-22-2024

### Market Drivers:

- Rising development in CD47-targeting anti-cancer therapies
- Growing Demands for cost-effective cancer treatments

### Market Obstacles:


- Therapeutic effectiveness
- Safety concerns

**Combination therapies** will dominate the global market owing to their enhanced efficacy and specificity towards the cancer cells.


## CD47-Targeting Therapeutics Landscape Analysis

### Drug Type

- Biologics 361
- Peptides 9
- Others 7
- Drug Conjugates 5
- Small Molecules (>350 - 500 Da) 2
- Small Molecules (>500 - 750 Da) 2
- Small Molecules (>750 Da) 1
- Small Molecules (0 - 350 Da) 1



### Highest Phase




Source: Cortellis Drug Discovery Intelligence




# Product Mechanism of Action and Advantages Over Current CD47 Inhibitors

## Anti-CD47 Antibody Blocks CD47 and SIRP $\alpha$ Interaction on Both Tumor Cells and on Red Blood Cells




## DBPR22998 – Oral Small Molecule IsoQC (QPCTL) Inhibitor Targeting CD47 and SIRP $\alpha$ "Don't Eat Me" Signal




# Key POC Data


## Key POC Data – 1




## Key POC Data – 2



## Key POC Data – 3



## Key POC Data – 4





# Competitive Landscape and Target Product Profiles

# DBPR22998: Product Summary

## Key Features

- An orally bioavailable small molecule isoQC (QPCTL) inhibitor modulating CD47-SIRP $\alpha$  "Do not eat me" cancer immune checkpoint activities
- Target post translational modification process of CD47 protein synthesis
- Opportunity for combination with anti-tumor antibody therapeutics, radiation, chemotherapy and immune checkpoint inhibitors (ICIs)

## Pharmaceutical Development

- Crystalline form identified; physicochemical properties/pre-formulation/formulation evaluation completed
- Preclinical kilogram-scale production of the active pharmaceutical ingredient (API) available
- Non-GLP 14-day repeated-dose toxicity studies in rats completed, providing valuable insights into the safety profile

## Intellectual Properties

- Substance patents: US, China, Taiwan, Japan, Korea, Canada, India, Singapore and Australia 9 countries granted
- Cancer indication patents: Taiwan patent granted, PTC patent applications under review

## Market Positioning

- As opposed to antibody approaches in clinical development, our small molecule isoQC (QPCTL) inhibitor DBPR22998 is a best-in-class and innovative therapeutic approach for boosting the efficiency of cancer immunotherapy while avoiding anti-CD47 antibody-induced anemia and thrombocytopenia

## Business Opportunities

- Technology transfer/co-development